Answers are grounded in this paper and cite their sources.
This analysis shows apremilast as a potential first-line systemic option for pediatric psoriasis, suggesting cost-effective benefits.
Although the efficacy of apremilast is lower compared to modern biologics (e.g. secukinumab, ixekizumab), the drug offers unique practical advantages: oral administration, absence of pre-treatment screening for tuberculosis and chronic hepatitis, and no requirement for laboratory monitoring. With patent expiration and the arrival of generics, apremilast may represent a potential cost-effective 'first-line systemic' option for pediatric patients who are not candidates for or are reluctant to accept injectable therapies.
No takes yet. Share an insight, caveat, or question.
Lernia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: